期刊文献+

遗传性凝血因子Ⅶ缺陷症伴组织因子异常的研究 被引量:1

Studies on inherited coagulation factor Ⅶ deficiency and tissue factor abnormality in a pedigree
原文传递
导出
摘要 目的探讨1个遗传性凝血因子Ⅶ(FⅦ)缺陷症伴组织因子异常家系的临床出血机制。方法用 DNA 直接测序法对先证者 FⅦ及组织因子(TF)基因的全部外显子及其侧翼5′和3′非翻译区进行分析,寻找突变基因。反向测序证实所发现的突变。用 RT-PCR 及筑巢式 PCR 扩增先证者 FⅦcDNA,检测 FⅦ基因大的缺失和(或)插入突变。对其家系成员作突变基因检测。结果在先证者 FⅦ基因启动子区检测到-55C→T 杂合突变。该突变来自先证者的母亲,其姐姐也带有同样的杂合突变。其他家系成员的 FⅦ基因未见突型。在先证者及所有家系成员的 TF 基因中均发现了9363C→T(Argl31Trp)杂合多态性,9363T 基因杂合频率为2.63%。结论首次报道先证者的临床出血与 FⅦ杂合突变及 TF 的杂合多态性有关。 Objective To investigate the mechanism of clinical haemorrhage in an inherited coagulation factor Ⅶ (F Ⅶ ) deficiency and tissue factor abnormality pedigree. Methods All exons, exon-intron boundaries and the 3', 5' untranslated sequences of FⅦ and tissue factor(TF) genes were amplified by PCR and sequenced directly, Any mutation identified by direct sequencing was confirmed by reverse sequencing. FⅦ cDNA of the proband was synthesized with random primers and amplified by nest PCR. Results 55C→ T heterozygous mutation located in promoter of FⅦ gene was identified in the proband, The heterozygous mutation was derived from his mother. Tracing the other pedigree members found that his sister had the same heterozygous mutation and the others had wild-type FⅦ genes. A 9363 C→T (Argl31Tip) heterozygous polymorphism in TF gene, which was 2.63% frequencey of T allele polymorphism, was found in all of the pedigree members. Conclusion It was the first report that the - 55C→T heterozygous mutation in FⅦ gene and the Argl31Trp heterozygous polymoIphism in TF gene explained the clinical symptom of the proband,
出处 《中华血液学杂志》 CAS CSCD 北大核心 2006年第3期150-153,共4页 Chinese Journal of Hematology
基金 上海市科委科技发展基金(012035)
关键词 基因 因子Ⅶ 组织因子 基因突变 基因多态性 临床症状 Gene, factor Ⅶ Tissue factor Gene mutation Gene polymorphism Clinical
  • 相关文献

参考文献10

  • 1Zawadzki C,Preudhomme C,Gaveriaux V,et al.The Arg200Trp mutation in the human tissue factor gene.Thromb Haemost,2002,87:540-541.
  • 2McVey JH,Boswell E,Mumford AD,et al.Factor Ⅶ deficiency and the FⅦ mutation database.Hum Mutat,2001,17:3-17.
  • 3Giansily-Blaizot M,Verdier R,Biron-Adreani C,et al.Analysis of biological phenotypes from 42 patients with inherited factor Ⅶ deficiency:can biological tests predict the bleeding risk? Haematologica,2004,89:704-709.
  • 4Pollak ES,Hung HL,Godin W,et al.Functional characterization of the human factor Ⅶ 5'-flanking region.J Biol Chem,1996,271:1738-1747.
  • 5Arbini AA,Pollak ES,Bayleran JK,et al.Severe factor Ⅶ deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor Ⅶ promoter.Blood,1997 ,89 :176-182.
  • 6Carew JA,Pollak ES,Lopaciuk S,et al.A new mutation in the HNF4 binding region of the factor Ⅶ promoter in a patient with severe factor Ⅶ deficiency.Blood,2000,96:4370-4372.
  • 7Erlich J,Parry GN,Fearns C,et al.Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation.Proc Natl Acad Sci U S A,1999,96:8138-8143.
  • 8Pawlinski R,Fernandes A,Kehrle B,et al.Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction.Proc Natl Acad Sci U S A,2002,99:15333-15338.
  • 9Reny JL,Laurendeau I,Fontana P,et al.The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers.Thromb Haemost,2004,91:248-254.
  • 10George J,Broze JR.The tissue factor pathway of coagulation.In:Thrombosis and Hemorrhage,3rd ed.Baltimore:Williams and Wilkins,Philadelphia PA,2003.62-80.

同被引文献21

  • 1Wang ZY, Xie JX, Xu FY,et al. Deficiencies in plasma thromboplastin factors[ J]. Chin Med J,1958,76(3) :243 -252.
  • 2陆德炎 孙关林 陈竺 等.硫杂脯氨酸对L6565小鼠骨髓细胞在扩散盒中增殖的影响.上海第二医学院学报,1983,3(4):46-50.
  • 3Huang ME, Ye YC, Chen SR, et al. An-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia: report of 6 cases[J]. Chin Med J. (Engl) ,1987, 100(12):949 -953.
  • 4Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia[ J]. Blood ,1988, 72(2) :567 -572.
  • 5Chen SJ, Zhu YL, Tong JH, et al: Rearrangements in the second intron of the RARA gene are present in a large majority of patients with APL and are used as molecular marker for retioic acid induced leukemia cell differentiation [ J ]. Blood, 1991,78 ( 10 ) : 2696 - 2701.
  • 6Chen SJ, Zelent A, Tong JH, et al. Rearrangements of the retinoic acid receptor alpha and promyeloeytic leukemia zinc finger genes resuiting from t( 11 ;17) ( q23 ;q21 ) in a patient with acute promyelocytic leukemia [ J ]. J Clin. Invest, 1993,91 (5) : 2260 - 2267.
  • 7Chen Z, Brand NJ, Chen A, et al, Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t( 11 ;17 ) translocation associated with acute promyelocytic leukaemia[J]. EMBO J, 1993, 12(3) :1161 -1167.
  • 8I Chen GQ, Shl XG, Tang W, et al. Use of arsenic trioxide ( As2O3 )in the treatment of acute promyelocytic leukemia (APL) , 1: As2O3 exerts dose-dependent dual effects on APL cells[ J]. Blood, 1997, 89(9) :3345 -3353.
  • 9Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable [ J ]. Blood,2008,111 ( 5 ) :2505 - 2515.
  • 10Jing Y, Wang L, Xia L, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo[ J]. Blood ,2001, 97( 1 ) :264 -269.

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部